Enrollment has finished ahead of schedule in a Phase 2 clinical trial testing Calluna Pharma‘s experimental…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Abnormalities in DNA methylation — a type of genetic modification that can alter the activity of a gene without changing…
A protein called PIEZO1, which helps cells in blood vessels detect mechanical forces, plays a key role in driving…
The U.S. Food and Drug Administration (FDA) has approved a generic version of Ofev (nintedanib) for easing lung scarring…
A compound called orcinol glucoside (OG) can reduce lung inflammation and scarring in mouse and cell models of idiopathic…
Treatment with Tyvaso (treprostinil) outperformed a placebo at preserving lung function and preventing clinical worsening — meaning, it led to…
Following the lifting of a regulatory hold late last year, a U.S. clinical trial testing LTI-03, an inhaled therapy for…
Regulatory authorities in both the U.S. and the European Union have granted orphan drug status to deupirfenidone (LYT-100), an oral…
Mutations in the ACVRL1Â gene may play a role in the development of idiopathic pulmonary fibrosis (IPF), and targeting the…
Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in…